ReviewEClinicalMedicine2025
The Global Fund, Cervical Cancer, and HPV infections: what can low- and middle-income countries do to accelerate progress by 2030?
Review in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- HPV in breast cancer: prevalence and comparison with healthy tissue-a systematic review and meta-analysis.Cancer causes & control : CCC · 2026Pooled it
- Sentinel lymph node biopsy versus lymphadenectomy in early-stage cervical cancer: a meta-analysis of oncologic outcomes and surgical morbidity.Frontiers in oncology · 2026Pooled it
- Pooled it
- Follow-up rescreening among women living with human immunodeficiency virus who tested positive and treated for cervical pre-cancer lesions in South Ethiopia.The oncologist · 2026Article
- Article
- Artificial Intelligence in Cervical Cytology: Opportunities and Limitations in Screening, Triage, and Diagnostic Support.Diagnostics (Basel, Switzerland) · 2026Review
- Optimizing cervical cancer diagnosis with a hybrid deep neural network and progressive resizing on pap smear WSIs.Scientific reports · 2026Article
- The changing landscape of oncology clinical trials in Latin America.Nature reviews. Clinical oncology · 2026Article
- Cervical cancer prevention behaviors and determinants among Indigenous women in rural Nepal.Health promotion international · 2026Article
- Cell cycle gene expression and microbial profiles associated with HPV related cervical neoplasia and cervical microbiome shifts.Scientific reports · 2026Article
- Review
- Article
- Molecular subtypes of breast cancer in Jamaican women: high prevalence of triple-negative and HER2 + disease.Breast cancer research : BCR · 2026Article
- Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials.Frontiers in pharmacology · 2026Review
- Trust buffers price-related barriers to HPV vaccination among female college students: a cross-sectional study in China based on the 3C model.Frontiers in public health · 2026Article
- Global determinants of cervical cancer outcomes: a health systems analysis.BMJ oncology · 2026Article
- Female cancers in adolescent and young adult women: global inequities and 2050 burden estimates from GLOBOCAN 2022.Frontiers in oncology · 2026Article
- Single-cell and spatial transcriptomic profiling reveals distinct tumor microenvironment dynamics in cervical adenocarcinoma and squamous cell carcinoma.Communications biology · 2025Article
- Fund contraction challenges for supplies for maternal and newborn health services in low- and middle-income countries: a scoping review.BMC public health · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The footprint of cervical cancer mirrors the impact of global inequity and inequality on the right to health for girls and women. While today, cervical cancer is a relatively rare cause of death in Europe, North America, and Australia, almost 94% of deaths in 2022 occurred in low- and middle-income countries (LMICs). Governments adopted the WHO global strategy to eliminate cervical cancer. Still, the stark reality is that many countries may not reach the 90:70:90 targets by 2030 without political commitment and a sense of urgency. We call for enhanced advocacy for the right to prevention services and political actions to mobilise global funding, local philanthropic support, and innovative financing. During the COVID-19 pandemic, an African coalition raised over $20 million to mitigate the impact of the pandemic. Positive lessons from this response should be replicated to save millions of women and girls at risk of cervical cancer in LMICs. There is a need for a global fund for cancer; regional blocs like the African Union need to recognise the disproportionate burden and establish continental funding mechanisms to enable high-burden countries to make crucial upfront health systems investments that will put their countries on the pathway to cervical cancer elimination. Funding: This study was not funded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.